Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Personalized Radiotherapy in Cancer Care
share announcement

Personalized Radiotherapy in Cancer Care

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 October 2024 | Viewed by 2679

Special Issue Editors

Prof. Dr. Bin S. Teh

E-Mail Website
Guest Editor
Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA
Interests: innovative radiation oncology technologies; stereotactic radiosurgery; gamma knife; stereotactic body radiation therapy; image-guided radiation therapy; combined immunotherapy and radiotherapy
Dr. Waqar M. Haque

E-Mail Website
Guest Editor
Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA
Interests: brachytherapy; breast cancer; radiation oncology

Special Issue Information

Dear Colleagues,

In 2004, the 21-gene recurrence score (RS) was established as the first predictive gene test for patients with hormonal receptor positive and HER-2 negative breast cancer who would not benefit from chemotherapy. Since then, numerous predictive biomarkers have been discovered, which has allowed us to tailor treatments to patients to offer them the best chance of survival, while also minimizing treatment-related toxicity. While many of the new predictive biomarkers involve modified systemic therapy, to the focus is now on optimizing radiation treatments. Predictive genetic tests and the presence of biomarkers are being studied to optimize radiation doses and volumes. This Special Issue hopes to highlight the current status and future plans of personalized radiation therapy for patients with cancer at different disease sites.

Prof. Dr. Bin S. Teh
Dr. Waqar M. Haque
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • predictive biomarkers
  • treatment-related toxicity
  • radiation treatments
  • radiation dose and volume
  • personalized radiation therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 18600 KiB  
Article
Validation of In Vitro Trained Transcriptomic Radiosensitivity Signatures in Clinical Cohorts
by John D. O’Connor, Ian M. Overton and Stephen J. McMahon
Cancers 2023, 15(13), 3504; https://doi.org/10.3390/cancers15133504 - 05 Jul 2023
Viewed by 885
Abstract
Transcriptomic personalisation of radiation therapy has gained considerable interest in recent years. However, independent model testing on in vitro data has shown poor performance. In this work, we assess the reproducibility in clinical applications of radiosensitivity signatures. Agreement between radiosensitivity predictions from published [...] Read more.
Transcriptomic personalisation of radiation therapy has gained considerable interest in recent years. However, independent model testing on in vitro data has shown poor performance. In this work, we assess the reproducibility in clinical applications of radiosensitivity signatures. Agreement between radiosensitivity predictions from published signatures using different microarray normalization methods was assessed. Control signatures developed from resampled in vitro data were benchmarked in clinical cohorts. Survival analysis was performed using each gene in the clinical transcriptomic data, and gene set enrichment analysis was used to determine pathways related to model performance in predicting survival and recurrence. The normalisation approach impacted calculated radiosensitivity index (RSI) values. Indeed, the limits of agreement exceeded 20% with different normalisation approaches. No published signature significantly improved on the resampled controls for prediction of clinical outcomes. Functional annotation of gene models suggested that many overlapping biological processes are associated with cancer outcomes in RT treated and non-RT treated patients, including proliferation and immune responses. In summary, different normalisation methods should not be used interchangeably. The utility of published signatures remains unclear given the large proportion of genes relating to cancer outcome. Biological processes influencing outcome overlapped for patients treated with or without radiation suggest that existing signatures may lack specificity. Full article
(This article belongs to the Special Issue Personalized Radiotherapy in Cancer Care)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 344 KiB  
Review
Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders
by Pui Lam Yip, Rui You, Ming-Yuan Chen and Melvin L. K. Chua
Cancers 2024, 16(2), 383; https://doi.org/10.3390/cancers16020383 - 16 Jan 2024
Viewed by 1110
Abstract
Radiotherapy is the primary treatment modality for non-metastatic nasopharyngeal carcinoma (NPC) across all TN-stages. Locoregional control rates have been impressive even from the 2D radiotherapy (RT) era, except when the ability to deliver optimal dose coverage to the tumor is compromised. However, short- [...] Read more.
Radiotherapy is the primary treatment modality for non-metastatic nasopharyngeal carcinoma (NPC) across all TN-stages. Locoregional control rates have been impressive even from the 2D radiotherapy (RT) era, except when the ability to deliver optimal dose coverage to the tumor is compromised. However, short- and long-term complications following head and neck RT are potentially debilitating, and thus, there has been much research investigating technological advances in RT delivery over the past decades, with the primary goal of limiting normal tissue damage. On this note, with a plateau in gains of therapeutic ratio by modern RT techniques, future advances have to be focused on individualization of RT, both in terms of dose prescription and the delineation of target volumes. In this review, we analyzed the guidelines and evidence related to contouring methods, and dose prescription for early and locoregionally advanced (LA-) NPC. Next, with the preference for induction chemotherapy (IC) in patients with LA-NPC, we assessed the evidence concerning radiotherapy adaptations guided by IC response, as well as functional imaging and contour changes during treatment. Finally, we discussed on RT individualization that is guided by EBV DNA assessment, and its importance in the era of combinatorial immune checkpoint blockade therapy with RT. Full article
(This article belongs to the Special Issue Personalized Radiotherapy in Cancer Care)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Risk-Stratified Radiotherapy in Pediatric Cancer
Authors: Rituraj Upadhyay; Arnold C. Paulino
Affiliation: University of Texas MD Anderson Cancer Center
Abstract: While the cure rate of cancer in children has markedly improved in the last few decades, late effects continue to be a problem in survivors. Radiotherapy, which is a major component of treatment in many cancers, is one of the major agents responsible for late toxicity. In the past decade, radiotherapy has been omitted in patients achieving excellent response to chemotherapy such as in Hodgkin lymphoma and Wilms tumor with lung metastases. Likewise response to chemotherapy has been used to determine whether lower doses of radiation can be delivered in intracranial germinoma and pediatric nasopharyngeal carcinoma. Molecular subtyping in medulloblastoma is currently being employed and in WNT-pathway M0 tumors, reduction of radiotherapy dose to the craniospinal axis and tumor bed is currently being investigated. Finally, dose escalation is being performed in rhabdomyosarcoma > 5 cm who do not achieve a complete response to initial 9 weeks of chemotherapy to improve local control.

Back to TopTop